Dr. Reddy's Receives Second FDA Form 483 in a Month, This Time for Its Srikakulam Plant

summarizeSummary

Dr. Reddy's received a Form 483 with three observations from the USFDA after a July 20–29 inspection of its Srikakulam plant, the second FDA warning letter in five weeks.

check_boxKey Events · Product Development and Regulatory · RDY

• Second FDA Form 483 in Five Weeks

  The USFDA issued a Form 483 with three observations after a July 20–29 inspection of the FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh. This follows a Form 483 with seven observations at a biologics facility on June 26.

• Regulatory Risk Escalates

  Back-to-back Form 483s increase the likelihood of a Warning Letter or import alert, which could disrupt U.S. supplies and delay pending ANDA approvals—a critical risk given the company's recent semaglutide API quality failure.

• No Immediate Financial Impact Disclosed

  The filing does not quantify any financial impact, but remediation costs and potential revenue delays from approval holds could pressure margins in coming quarters.

• Response Timeline

  Dr. Reddy's states it will address the observations within the stipulated timeline, but no specific deadline is provided.

auto_awesomeAnalysis · RDY · Life Sciences

Following a July 20–29 inspection of the FTO-SEZ Process Unit-02 in Srikakulam, the USFDA issued a Form 483 with three observations. This marks the second such notice in just over a month—the first, carrying seven observations, stemmed from a biologics facility inspection in late June. The back-to-back regulatory findings heighten the risk of enforcement action and could stall pending product approvals, adding to the company's recent quality challenges with semaglutide API.